A.p. Pharma, Inc.

Alza Corporation

Pharmaceutical Delivery Systems, Inc.

Sri International

Nitto Electric Industrial Co., Ltd.

Advanced Polymer Systems, Inc.

Heron Therapeutics, Inc.

Merck + Co., Inc.

Sandoz Pharmaceuticals Corp.

Other

Nitto-denko Corporation

University of Utah Research Foundation

Bend Research, Inc.

Sandoz Pharm. Corp.

World Health Organization

Jorge Heller

Steven Y Ng

Steve Y Ng

Donald W Penhale

Wilfred A Skinner

Kenichiro Saito

Hui-Rong Shen

Hui Rong Shen

Richard W Baker

Nam S Choi

Michael Froix

Lin-Shu Liu

Nam Sok Choi

Stephen James Brocchini

Susumu Satoh

Martin A Katz

Sergio Nacht

Robert F Helwing

Ryan Tomlinson

Alma U Daniels

Ruth Duncan

Shane Garrett

Marcus M Klee

Hui-Rung Shen

A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.

Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron

Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron

Methods of treating emesis utilizing semi-solid delivery pharmaceutical compositions comprising granisetron

Process for preparing a semi-solid delivery vehicle comprising granisetron

This invention relates to graft copolymer delivery vehicles comprising a polyethyleneglycol-poly(ortho ester), and to controlled release pharmaceutical compositions comprising the delivery vehicle and an active agent. The graft copolymer delivery vehicles may be thermogels graft copolymers. The pharmaceutical compositions may be in the form of a topical, syringable, or injectable formulation for local controlled delivery of the active agent.

PEG-poly(ortho ester) graft copolymers and pharmaceutical compositions

Degradable polyacetal polymers and functionalized degradable polyacetal polymers have properties favorable for use in pharmaceutical and biomedical applications. The degradable polyacetal polymers are relatively stable at physiological pH with favorable biodistribution profiles, and degrade readily in low pH conditions. Conjugates of the polymers with drugs, especially anticancer drugs, and methods of treatment of cancer.

Degradable polyacetal polymers

Bioerodible poly(ortho esters) useful as orthopedic implants or vehicles for the sustained delivery of pharmaceutical, cosmetic and agricultural agents from dioxane-based di(ketene acetals). Block copolymers contain these bioerodible poly(ortho esters). These block copolymers have both hydrophilic and hydrophobic blocks. They form micelles in aqueous solution, making them suitable for encapsulation or solubilization of hydrophobic or water-insoluble materials; and they also form bioerodible matrices for the sustained release of active agents.

Bioerodible poly(ortho esters) from dioxane-based di(ketene acetals), and block copolymers containing them

Block copolymers based on poly(ortho esters) containing amine groups. These block copolymers have both hydrophilic and hydrophobic blocks. They form micelles in aqueous solution, making them suitable for encapsulation or solubilization of hydrophobic or water-insoluble materials; and they also form bioerodible matrices for the sustained release of active agents.

Block copolymers based on poly(ortho esters) containing amine groups

Pharmaceutical compositions using semi-solid delivery vehicle

Bioerodible poly(orthoesters) useful as orthopedic implants or vehicles for the sustained delivery of pharmaceutical, cosmetic and agricultural agents contain hydrogen bonding groups and &agr;-hydroxy acid-containing groups.

Bioerodible poly (orthoesters) from dioxolane-based diketene acetals

Growing community of inventors

Ashland, OR, United States of America

Jorge Heller